FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

1. Name and Address of Reporting Person* RAPPAPORT ANDREW (Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR					2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [OLMA] 3. Date of Earliest Transaction (Month/Day/Year) 09/18/2020						(Ch	eck all applic	cable) or (give title	Person(s) to Is 10% C Other below)	wner (specify
(Street) SAN FRANCI			94107 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3) 2. Transac Date (Month/D.				Transacti te onth/Day	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins 8) Code V	4. Secur Dispose 5) Amount	(A) or (D)	ed (A) or tr. 3, 4 and Price	5. Amour Securitie Beneficia Owned F Reported Transact (Instr. 3 a	nt of es Fally (following ling)	5. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date (Month/Day/Year) if any			4. Trar Cod	5. Number of ode (Instr. Derivative			6, Options, convertible securitie 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$4.824	09/18/2020		A		56,964		(1)	09/17/2030	Common Stock	56,964	\$0.00	56,964	D	
Stock Option (Right to Buy)	\$19	11/18/2020		A		21,520		(2)	11/17/2030	Common Stock	21,520	\$0.00	21,520	D	

Explanation of Responses:

- 1. The shares subject to the option are fully vested.
- 2. The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

/s/ John B. Moriarty, Jr., 11/19/2020 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.